## Lupin Limited (LUPIN) Stock Investment Report - December 20, 2024

**1. Company Overview:**

Lupin Limited is a pharmaceutical company listed on the National Stock Exchange of India (NSE) since September 10, 2001.  It operates in the Pharmaceuticals industry and holds a significant position within the Indian pharmaceutical sector, known for its generic and specialty drug manufacturing and marketing.

**2. Market Data Analysis:**

| Metric                     | Value          | Notes                                                                 |
|-----------------------------|-----------------|-------------------------------------------------------------------------|
| Current Price               | ₹2,149.75       |                                                                         |
| Percentage Change (PChange) | -0.61%          | Negative change indicating a slight downward trend in the day's trading. |
| Pre-Open Activity          | ₹2,165          | Higher than the previous close, suggesting initial buying interest.     |
| Week High                    | ₹2,312          | High point reached during the week.                                     |
| Week Low                     | ₹1,200.15       | Low point reached during the week, indicating significant volatility.    |
| VWAP                        | ₹2,161.83       | Volume Weighted Average Price for the day.                             |
| Sector PE                   | 37.21           | Price-to-Earnings ratio for the sector.                               |
| Symbol PE                   | 37.21           | Price-to-Earnings ratio for Lupin Limited.                             |
| Delivery Percentage         | 49.24%          | Relatively high delivery percentage suggests some degree of conviction. |
| Market Depth                | Low              | Order book data shows low market depth, indicating potential volatility.|


**3. Financial Performance:**

The following table summarizes Lupin's financial performance over the past five quarters.  Note that the data shows a profit after tax, which contradicts the provided data showing a loss after tax.  This discrepancy needs clarification from the original data source.  The analysis below assumes the provided profit after tax figures are correct.

| Quarter Ending      | Revenue (₹)     | Expenses (₹)    | Profit After Tax (₹) | EPS (₹)  |
|----------------------|-----------------|-----------------|-----------------------|---------|
| 30-Sep-2024          | 413,882         | 315,477         | 80,776                 | 17.71    |
| 30-Jun-2024          | 420,585         | 312,293         | 88,918                 | 19.51    |
| 31-Mar-2024          | 342,722         | 299,906         | 38,408                 | 8.43     |
| 31-Dec-2023          | 413,891         | 305,495         | 91,644                 | 20.14    |
| 30-Sep-2023          | 368,483         | 298,879         | 54,861                 | 12.06    |


**Key Financial Ratios (Further analysis required with clarified data):**  A comprehensive analysis of key ratios like Return on Equity (ROE), Return on Assets (ROA), Debt-to-Equity ratio, and Profit Margins is needed to fully assess financial health.  This requires clarification on the profit/loss discrepancy.

**4. Corporate Actions and Announcements:**

Lupin has consistently declared dividends over the past several years.  Recent announcements include dividend payments and various regulatory filings related to capital alterations, ESOPs, and rumour verifications.  The details of these announcements require further investigation to assess their impact on the stock price.

**5. Shareholding Patterns:**

| Quarter Ending | Promoter & Promoter Group (%) | Public (%) | Shares held by Employee Trusts (%) | Total (%) |
|-----------------|-----------------------------|------------|---------------------------------|-----------|
| 30-Sep-2023     | 47.06                        | 52.94      | 0.00                             | 100.00    |
| 31-Dec-2023     | 47.04                        | 52.96      | 0.00                             | 100.00    |
| 31-Mar-2024     | 47.01                        | 52.99      | 0.00                             | 100.00    |
| 30-Jun-2024     | 46.98                        | 53.02      | 0.00                             | 100.00    |
| 30-Sep-2024     | 46.96                        | 53.04      | 0.00                             | 100.00    |

Promoter holding has shown a slight downward trend over the past year, while public holding has increased correspondingly. This needs further investigation to determine the cause.

**6. Volatility and Risk Assessment:**

The stock exhibits significant volatility, as evidenced by the week's high and low prices.  The CM Annual Volatility of 31.91% further confirms this.  The low market depth adds to the risk profile.  A thorough risk assessment requires analyzing historical price data and calculating additional risk metrics like Beta and Sharpe Ratio.

**7. Advantages of Buying the Stock:**

* Consistent dividend payouts.
* Established presence in the pharmaceutical sector.

**8. Disadvantages and Risks:**

* High volatility.
* Uncertainty regarding the impact of recent announcements.
* Low market depth.
* Discrepancy in reported financial data (profit vs. loss).


**9. Investment Horizon Recommendations:**

* **Short-term (less than 3 months): Hold.** The current price movement is uncertain due to low market depth and recent announcements.  Waiting for clearer market trends is advisable.

* **Medium-term (3 to 12 months): Hold.**  The medium-term outlook depends on the clarification of the financial data discrepancy and the impact of corporate actions.  Further analysis is needed.

* **Long-term (1 year and beyond): Hold (with caution).**  Lupin's long-term prospects depend on its ability to navigate market competition and maintain consistent financial performance.  The current data is insufficient to make a strong buy recommendation.


**10. Stock and Analysis Scoring:**

**Stock Score (out of 10): 6/10**

* Financial Health: 4/10 (Requires clarification on profit/loss discrepancy and further ratio analysis)
* Market Performance: 5/10 (Moderate volatility and recent price decline)
* Volatility and Risk: 3/10 (High volatility and low market depth)
* Corporate Actions & Governance: 7/10 (Consistent dividend history, but requires further investigation of recent announcements)
* Shareholding Patterns: 6/10 (Slight decline in promoter holding warrants further investigation)

**Analysis Score (out of 10): 7/10**

* Completeness and Data Utilization: 8/10 (Most data used, but some information requires further investigation)
* Accuracy and Clarity: 6/10 (Analysis hampered by data inconsistencies)
* Professional Formatting: 9/10 (Report well-structured and easy to read)


**11. Professional Recommendation Summary:**

Based on the available data (with the caveat of the financial data discrepancy), a "Hold" recommendation is given for all investment horizons.  Further investigation is crucial to clarify the financial data, assess the impact of recent announcements, and perform a more comprehensive risk assessment before making a definitive buy or sell decision.  The high volatility and low market depth present significant risks for short-term investors.  Long-term investors should carefully monitor the company's financial performance and industry trends.
